The San Antonio Breast Cancer Symposium 2021 will begin tomorrow and will bring together the leading international experts on breast cancer in Texas until December 10th. The busy schedule can be followed in person or in web live streaming and as every year the mission of the meeting is to provide the state-of-the-art information on breast cancer research, from experimental biology to prevention, from diagnosis to therapy. The scientific program is very rich as usual, ranging from the exploration of the molecular and hormonal expression of breast tumors to the evolution of treatments in HER2 positive tumors, from news on metastatic or recurrent cancer to early stage breast cancer.
Michelangelo Foundation will also give an important contribution to the congress: on December 7th at 8am during the opening session Giampaolo Bianchini of the Department of Medical Oncology – San Raffaele Hospital in Milan and Scientific Coordinator of traslational studies on breast cancer in Michelangelo Foundation will discuss the latest data from the single-cell spatial analysis by imaging mass cytometry in patients enrolled in the NeoTRIP trial, designed and coordinated by the Michelangelo Foundation. This is a phase III clinical trial to evaluate the clinical benefits of adding a neoadjuvant immunotherapy with atezolizumab to chemotherapy with nab-paclitaxel and carboplatin in patients with high risk or locally advanced triple-negative breast cancer. Dr. Bianchini will show data indicating that imaging mass cytometry can provide a more comprehensive overview of neoplastic cells heterogeneity providing and offer predictive information, for example, of the benefit of immune checkpoints inhibitors.
During the congress, researchers collaborating with Michelangelo Foundation will also present 4 other works with data focusing mostly on the NeoTRIP trial: the additional studies will cover the effects of therapies on the immune microenvironment to the dynamics of gene expression predicting the pathological complete response, the evaluation of PD-L1 as a predictive biomarker and its dependence on the time of assessment and treatment received.
